Drugs / HDG1901
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06634927 | Sep → Nov 2024 | type 2 diabetes mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06739044 | Sep 2023 → Oct 2024 | type 2 diabetes mellitus | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDG1901 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06634927 ↗ |
| Route | Subcutaneous | “Participants will be given HDG1901 injection 0.25mg abdominal subcutaneous injection.” NCT06634927 ↗ |